HIK.L - Hikma Pharmaceuticals PLC

LSE - LSE Delayed Price. Currency in GBp

Hikma Pharmaceuticals PLC

1 New Burlington Place
London W1S 2HR
United Kingdom
44 20 7399 2760
http://www.hikma.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees8,400

Key Executives

NameTitlePayExercisedYear Born
Mr. Said Samih Taleb DarwazahExec. ChairmanN/AN/A1957
Mr. Mazen Samih Taleb DarwazahExec. Vice Chairman & Pres of MENAN/AN/A1958
Mr. Sigurdur Oli Olafsson Ph.D.CEO & Exec. DirectorN/AN/A1969
Mr. Khalid Walid Hussni NabilsiChief Financial OfficerN/AN/A1972
Dr. Surendera TyagiGroup Chief Scientific Officer and Global Head of R&DN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. The Generics segment develops and sells oral and other non-injectable generic products for retail market. The Branded segment develops, manufactures, and markets branded generics and in-licensed products to retail and hospital markets. The company offers products in various therapeutic areas, including respiratory, oncology, pain management, anti-infectives, cardiovascular, diabetes, and central nervous system. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Corporate Governance

Hikma Pharmaceuticals PLC’s ISS Governance QualityScore as of April 1, 2019 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.